Search All News
The way SARS-CoV-2 mutates in immunocompromised patients to escape Paxlovid could help chemists design better drugs that are more difficult for the virus to sidestep.
Columbia researchers have found why babies are susceptible to repeated bouts of common respiratory infections—but also have a unique weapon to fight off new pathogens that healthy adults lack.
Patients with mpox who were treated with the antiviral drug tecovirimat had similar outcomes regardless of HIV status, find researchers at Columbia University and Weill Cornell Medicine.
- July 5, 2022
The latest omicron subvariants—especially the currently dominant BA.4 and BA.5 forms—are even better at eluding vaccines and most treatments, find researchers at Columbia University.
- June 28, 2022
Community outreach and restricting online scheduling to certain zip codes helped increase vaccine uptake among Black and Hispanic residents, new study says.
- June 27, 2022
Columbia scientists have joined a regional consortium to accelerate the development of new drugs that target SARS-CoV-2, other coronaviruses, and viruses that could lead to future pandemics.
- June 14, 2022
In the wake of the COVID pandemic, Anne Moscona is bringing an appreciation for public outreach to her upcoming role as president of the American Society for Virology.
- April 7, 2022
Columbia researchers have uncovered how Gram-negative bacteria—which cause a variety of drug-resistant infections—build their protective outer layer, which could lead to more effective treatments.